New Rapid Lateral Flow Antigen COVID-19 Testing Platform Processes 200-300 People Each Hour and Reports Results in 15 Minutes
By LabMedica International staff writers Posted on 20 Oct 2020 |

Illustration
A new rapid lateral flow antigen COVID-19 testing platform gives testers the ability to process an unprecedented 200-300 people each hour and report results within 15 minutes utilizing testing kits from Quidel, BD and Abbott.
The COVID CleanPass system from Apollo Medco (Atlanta, GA, USA) is a mobile app-linked, HIPAA compliant, cloud secure and data-backed COVID-19 testing platform. Straight forward and effortless to operate, its built-in software walks anyone through all and every step of testing. Its trouble-free transportability and total weight of less than 20 pounds makes any location perfect for use. Its bulletproof and waterproof case floats and protects all electronics inside, no matter how harsh the environment. In case of power failure, its eight-hour battery or solar powered panels ensure that testing continues.
Hassle-free, simple to operate, and compatible with worldwide power sources, the COVID CleanPass is a reliable system that is enabling businesses across the globe to reopen and start growing with absolute peace of mind. With its compact form and overhead airline compliance, immediate global deployment to the next viral outbreak is actually possible. Currently, Apollo Medco is beta testing its COVID-19 testing platform and applying for Emergency Use Authorization from the US Food and Drug Administration which is expected in November 2020. Distribution of the new COVID CleanPass system is then expected to begin in late November 2020.
"Our new COVID CleanPass platform is the most advanced, quality-assured, rapid testing platform in the world," said Apollo Medco President & CEO Ken Dunwody. "We've supercharged the overall COVID testing process by delivering fast and accurate results to the patient in an efficient manner. The front-end of our platform includes our Apollo 'Mission Control' diagnostic unit while the back-end of our platform includes our mobile app-linked, cloud secure, HIPAA compliant test reporting system which includes a dynamic Web portal that maps, tracks and reports COVID hot zones in real time."
"Each Apollo Medco testing system is contained in a portable rugged case and includes a battery that lasts 10 hours, iPad with the proprietary mobile app system, time tracking system, printer and a universal lateral flow analysis device. All testing companies will have access to our HIPPA compliant Web portal for accepting new testing requests, scheduling, assigning systems to testers and managing testing assignments. Automatic reporting of all COVID-19 tests through the Apollo Medco COVID CleanPass system will enable testing companies to provide quick, accurate information," added Dunwody.
Related Links:
Apollo Medco
The COVID CleanPass system from Apollo Medco (Atlanta, GA, USA) is a mobile app-linked, HIPAA compliant, cloud secure and data-backed COVID-19 testing platform. Straight forward and effortless to operate, its built-in software walks anyone through all and every step of testing. Its trouble-free transportability and total weight of less than 20 pounds makes any location perfect for use. Its bulletproof and waterproof case floats and protects all electronics inside, no matter how harsh the environment. In case of power failure, its eight-hour battery or solar powered panels ensure that testing continues.
Hassle-free, simple to operate, and compatible with worldwide power sources, the COVID CleanPass is a reliable system that is enabling businesses across the globe to reopen and start growing with absolute peace of mind. With its compact form and overhead airline compliance, immediate global deployment to the next viral outbreak is actually possible. Currently, Apollo Medco is beta testing its COVID-19 testing platform and applying for Emergency Use Authorization from the US Food and Drug Administration which is expected in November 2020. Distribution of the new COVID CleanPass system is then expected to begin in late November 2020.
"Our new COVID CleanPass platform is the most advanced, quality-assured, rapid testing platform in the world," said Apollo Medco President & CEO Ken Dunwody. "We've supercharged the overall COVID testing process by delivering fast and accurate results to the patient in an efficient manner. The front-end of our platform includes our Apollo 'Mission Control' diagnostic unit while the back-end of our platform includes our mobile app-linked, cloud secure, HIPAA compliant test reporting system which includes a dynamic Web portal that maps, tracks and reports COVID hot zones in real time."
"Each Apollo Medco testing system is contained in a portable rugged case and includes a battery that lasts 10 hours, iPad with the proprietary mobile app system, time tracking system, printer and a universal lateral flow analysis device. All testing companies will have access to our HIPPA compliant Web portal for accepting new testing requests, scheduling, assigning systems to testers and managing testing assignments. Automatic reporting of all COVID-19 tests through the Apollo Medco COVID CleanPass system will enable testing companies to provide quick, accurate information," added Dunwody.
Related Links:
Apollo Medco
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more